ABSTRACT
INTRODUCTION
Adrenal incidentaloma is an adrenal tumor; its existence is unknown and was found incidentally during radiologic examination. A tumor is not classified as adrenal incidentaloma if it is found on imaging studies to look for metastases, or previous suspicion of adrenal abnormalities. 1 Some decades ago, autopsy studies reported adrenal tumor was found on 32% cases; however, in pre-mortal condition, no adrenal tumor was suspected. [2] [3] [4] At that time, the tumor was classified as adrenocortical tumor which was asymptomatic and rare. 1 Since the imaging techniques are getting more and more advanced, such as ultrasonography (USG); computerized tomography (CT) scanning and magnetic resonance imaging (MRI), consequently adrenal tumor is easier to be detected; hence, the diagnosis of adrenal incidentaloma is more frequently made and is labeled as "diseases of the modern technology". 5, 6 The incidence and prevalence of adrenal incidentaloma is unspecified, but on autopsy studies, the incidence of asymptomatic adrenal tumor varies from 1.4%-8.7%. The prevalence of adrenal incidentaloma increases with age, less than 1% in patients below 30 years of age and increases to 7% in patients over 70 years of age. There is no difference in prevalence based on race and sex. 7, 8 Approximately 80% of adrenal incidentaloma is benign and does not secrete hormone (nonhypersecreting), with size less than 2 cm. Several studies report that adrenal incidentaloma is often found unilaterally, often in right adrenal; however, in 2-10% of cases is found bilaterally. Presenting symptom depends on tumor's location and usually atypical until detected later incidentally through imaging.
On February 2003, the National Institute of Health (NIH) issued a consensus on adrenal incidentaloma, in order to help clinician on evaluating and planning a therapy, Even though adrenal incidentaloma is labeled as "diseases of the modern technology", but actually the classification of adrenal incidentaloma does not differ from the previously established classification of adrenal tumor. 10 Adrenal consists of cortex and medulla. Adrenal cortex produces three essential steroids, which are glucocorticoids, mineralocorticoids, and adrenal androgen. Adrenal medulla secretes cathecolamines. 11 The study of AI-SIE also reported that the majority of hypersecreting tumor is cortical tumor, particularly the cortisol secreting adenoma.
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DIAGNOSTIC APPROACH OF ADRENAL INCIDENTALOMA
The next step subsequent to diagnosis of adrenal incidentaloma is determining the tumor's type by means of further evaluation. The optimal diagnostic approach is still controversial; however, the National Institute of Health (NIH) state-of-the science conference statement proposes a diagnostic algorithm to help the clinicians. Most adrenal lesion is benign and hormonally inactive (non-hypersecreting adenoma), thus costeffective management is important for patient's benefit, by avoiding unnecessary diagnostic intervention. 2, 8, 16, 17 Diagnostic approach of adrenal incidentaloma, according to NIH state-of-the science conference, intends to determine the type of adrenal tumor and focuses on two main problems, which are, whether the lesion is hormonally active although there are lack of characteristic clinical signs, and how great is the risk of it to be malignant. 1, 18 These problems can be answered through a meticulous history taking, hormone evaluation and other additional examination as necessary.
Clinical Manifestation
A careful history taking is needed to differentiate whether the tumor is non-hypersecreting, hypersecreting, or others. Approximately 80% of adrenal incidentaloma cases are asymptomatic or atypical, although if it is analyzed retrospectively and thoroughly, symptoms that represent adrenal hormone hyper-secretion are found in some cases. Clinical manifestation as complained depends on the type of hormone being secreted by the tumor. If there is no hormonal imbalance associated symptoms, then the non-hypersecreting tumor may be considered. Study Group of the Italian Society of Endocrinology on Adrenal Incidentaloma (AI-SIE) classified adrenal incidentaloma into non-hypersecreting adrenal adenoma, hypersecreting tumor, primary adrenal carcinoma, other adrenal mass and metastases. Mantero et al 12 conducted a study of 1096 cases for 15 years, reported that most of adrenal incidentaloma is non-hypersecreting adrenal adenoma (74%). Hypersecreting tumor is on the second rank (14.8%), followed with other adrenal mass (6.4%), primary adrenal carcinoma (4%) and metastases (less than 1%). 12, 13 Hypersecreting tumor consists of cortisol secreting adenoma and it manifests as Subclinical Cushing's Syndrome (SCSS), aldosteronomas which are aldosteronsecreting adrenal cortex adenomas manifested as Conn's disease, and pheochromocytoma, which is an adrenal medulla tumor. These three tumors are types of tumor which are closely associated with cardiometabolic risk and requiring proper management. Other type of tumor that should to be noticed is primary adrenal carcinoma, because it needs appropriate therapeutic approach. Sub-clinical Cushing's syndrome is reported to be closely associated with high cardio-metabolic risk, though without any typical symptoms, since cortisol acts as insulin's counteract, i.e. increases sympathetic activity, vascular tone, hypercoagulability and arterial hypertension. 5 This has been proven through a study conducted by Rossi et al. 23 reporting that there is a correlation between hypertension, insulin resistance, glucose and lipid metabolic disorders, obesity (cluster metabolic syndrome), and osteoporosis on SCSS subjects. AI-SIE study reported that the prevalence of hypertension is 41% and diabetes is 10% on SCSS subjects. 12 The other study by Tauchmanova et al 24 27 in 1981 reported that only a quarter of pheochromocytoma cases were detected ante mortem, the remainders were found on post mortem. Most patients die due to cardiovascular complication even before pheochromocytoma was diagnosed. Retrospective analysis shows that 90% of pheochromocytoma patients have a history of hypertension with pathognomonic pheochromocytoma triad, including headache, perspiration, and palpitation, which make it possible to be detected. On the other side, such triad symptoms rarely noticed and it is missed by the clinicians due to its paroxysmal quality and considered as a common discomfort. Approximately 10-40% of pheochromocytoma on adrenal incidentaloma is asymptomatic and it is called sub clinical pheochromocytoma. 26, 28, 29 2. Other adrenal mass and metastases
Other adrenal masses include myelolipoma, cyst and ganglioneuroma; however, they are rare and no typical or characteristic symptom is found. Adrenal is the most common site of metastases. The major sources of metastases are breast, lung, kidney, melanoma and lymphoma. Adrenal metastases, which is incidentally found and diagnosed as adrenal incidentaloma, is generally asymptomatic.
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Hormonal Testing
Although most of adrenal incidentaloma are nonhypersecreting adenoma; studies on hormonal screening showed 20% of adrenal incidentaloma was asymptomatic hormone hypersecreting tumor. Consensus issued by NIH state-of-the science conference and AI-SIE suggest hormonal screening for every patient with adrenal incidentaloma. 1, 5 Preliminary hormonal screening, consisting of 24-hour urinary cathecolamines and 1 mg dexamethasone suppression test, are performed in patients with diagnosis of adrenal incidentaloma. If the patient has hypertension, then aldosteron/plasma renin activity (PRA) ratio is also tested. A positive result of 24-hour urine cathecolamines supports the pheochromocytoma diagnosis, although negative result does not completely rule out pheochromocytoma. A positive 1 mg dexamethasone suppression test supports SCSS diagnosis; while an abnormal aldosteron/plasma renin activity (PRA) ratio supports the diagnosis of Conn's disease. Routine test for sex hormone hypersecretion is not indicated in the literatures due to the small number of prevalence.
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Further hormonal evaluation is required to confirm the diagnosis if one of the preliminary hormonal evaluations shows positive result. Further test to establish the diagnosis of pheochromocytoma is the metanephrine/normetanephrine urine test. For SCSS, subsequent corticotropin-releasing hormone (CRF) test or measurement of urinary free cortisol (UFC) level is performed. In addition, NaCl suppression test and measurement of aldosteron plasma level are performed for Conn's disease. 11, 28 When the result of hormonal evaluation is abnormal, hormone non-hypersecreting tumor is considered and followed by re-evaluation of imaging studies to determine the next step. 1, 12, 18 The bigger the size, the greater possibility of tumor actively secretes hormone. Approximately 40% of tumor sized 6 cm in diameter is hypersecreting tumor (figure 2). Tumor with the size less than 2 cm rarely has abnormal hormonal testing, except for aldosteron secreting tumor since although it has small size, this tumor can still cause significant hypertension. 18 On the contrary, inhomogeneous lesion with irregular border and enhancement to contrast administration generally illustrate a malignancy. Tumor metastases shows irregular border, found bilaterally in both glands, with irregular circular enhancement. 1 MRI is regarded as more superior than abdomen CT scan in identifying pheochromocytoma and carcinoma infiltration. 5, 16 Adrenal scintigraphy is performed on large nonhypersecreting lesion (>3 cm) with inconclusive abdomen CT scan. Adrenal scintigraphy uses iodomethyl-norcholesterol method and 131 metaiodobnzyl guanidine (MIBG).
131 I-NP-59 is considered more appropriate for SCSS screening; whereas MIBG is more suggested for sub-clinical/silent pheochromocytoma. 5, 30, 31 The latest imaging study is Positron Emission Tomography (PET) which uses 18 F-fluorodeoxyglucose (FDG). The advantage of FDG-PET includes its ability to differentiate primary adrenal tumor from metastases of adrenal tumor by non-invasive technique.
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Fine Needle Aspiration (FNA)
Adrenal FNA is not a routine test for adrenal incidentaloma. Cook et al. 22 stated that FNA is only used when metastases of the tumor to adrenal gland is suspected. FNA may assist identifying the metastases, but it cannot differentiate an adenoma from primary adrenal carcinoma. A study by Kieven et al. 33 reported that FNA has 91% sensitivity and 97% specificity in identifying metastases.
It is better to perform FNA only when the type of adrenal tumor cannot be determined, neither clinically nor by hormonal testing. The diagnosis of pheochromocytoma must be ruled out prior to FNA, because it may potentially cause hypertensive crisis or sudden death.
MANAGEMENT
The management of adrenal incidentaloma is still controversial. The main problem that needs to ponder prior to deciding therapy plan is the same as diagnostic approach plan, i.e. assessing the characteristics of the tumor, whether it is hormonally active or malignant. 5, 35 Adrenalectomy is the best choice for hormone hypersecreting type of adrenal incidentaloma with typical symptoms in patients with adrenal incidentaloma, especially if the tumor types are Conn's disease and pheochromocytoma. The management of SCSS patient is still controversial. A study reported that several SCSS patients may present with metabolic disorder such as insulin resistance, or even progressing to Cushing's syndrome, hence vigilant observation is needed, and adrenalectomy is performed if necessary. 
Imaging Studies
Once the diagnosis of adrenal incidentaloma has been confirmed and hormonal testing to classify the tumor has been performed, the next step is to re-evaluate the tumor size based on previous imaging study. If the initial imaging study cannot determine the tumor size, then more sensitive imaging study is required. Imaging studies including abdomen CT scan, MRI and adrenal scintigraphy are recommended. 22, 30 Of all other radiologic examinations, abdomen CT scan is the best choice since it is considered to be costeffective. Homogeneous lesion with size less than 4 cm and density less than 15 HU, without enhancement to contrast administration, usually illustrates benign tumor.
The size of adrenal incidentaloma can be a parameter in differentiating benign and malignant tumor, although it is hormonally inactive. The size of tumor is measured by CT scan or MRI. Tumor with size less than 4 cm is generally benign, hence adrenalectomy is not recommended; however, repeated CT scan is needed every 3-6 months on the first year and every year for 3 years period, and hormonal re-evaluation should be performed annually. If hormonal status becomes active or the size of the tumor increases, then adrenalectomy is performed. Malignancy is suspected on tumor with size more than 4 cm or lesion with irregular border. Adrenal scintigraphy and cytological examination can initially be performed to lesion with suspected malignancy, or surgical measure may be directly performed. Arnaldi et al 1 suggested surgical removal on tumor sized more than 4 cm, without initially performing adrenal scintigraphy or cytological examination. Adrenalectomy is performed on patients with negative result of adrenal scintigraphy, thus having significant probability towards malignancy, and on patients with Adrenalectomy can be performed by methods of laparatomy or laparoscopic. Tumor size and tumor malignancy status determine the surgical method. If the tumor size is less than 10 cm, laparascopic adrenalectomy can be performed. If the tumor size is more than 10 cm, laparatomy is suggested. The surgical method-of-choice for malignancy is laparatomy. 36 Studies demonstrated that laparascopic adrenalectomy has lower morbidity and mortality rate, ranges from 5-10% and 1-2%. 18 , 34
CONCLUSION
The prognosis of adrenal incidentaloma depends on the tumor. The majority of adrenal incidentaloma is nonhypersecreting tumor, thus having good prognosis. In general, the size of non-hypersecreting tumor is stabile, but around 5-20% of the tumors increase in size, whereas 3-4% may shrink. Approximately 20% of adrenal incidentaloma can develop into hypersecreting tumor in 3-4 years period, particularly tumor with size > 3 cm.
Barzon et al
37 conducted 2 year-follow up in 75 patients with non-hypersecreting tumor. They reported that 10% of the non-hypersecreting tumor develops into hypersecreting tumor. Other study by Libe et al 38 observed 64 patients for approximately 10 years reported that there is a correlation between tumor size increment and transformation of the tumor from non-hypersecreting into hypersecreting type.
The prognosis of hypersecreting tumor will get worse if no surgical measure is taken, because the possible complication due to hypersecreting hormone. Prognosis after surgical removal of hypersecreting tumor is generally good, because the removal can decrease cardiovascular risk such as hypertension, hyperglycemia and hypercholesterolemia. 14 The prognosis of tumor metastases depends on histological profile, staging and location of the primary tumor. Approximately 25% of the tumor with the size > 6 cm is adrenocortical carcinoma with very poor prognosis. A study on adrenal carcinoma reported that the average 5-year survival rate was only 34%. 14 
